Ron Do
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ron Do has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Girish N. Nadkarni
The Windreich Department of Artificial Intelligence and Human Health, Mount Sinai Medical Center, NY, USA
29 shared publications - Daniel M. Jordan
Icahn School of Medicine at Mount Sinai
20 shared publications Ghislain Rocheleau
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, 3 East 101st Street, Room 803, New York, NY, USA
20 shared publications- Iain S. Forrest
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
17 shared publications - Pradeep Natarajan
Massachusetts General Hospital
17 shared publications - Ruth J. F. Loos
Icahn School of Medicine at Mount Sinai
17 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Wiley in Genetic Epidemiology
- Vol. 50 (6) , e70052
The Omnicausal Model Reveals the Highly Polyfactorial Nature of Complex Diseases
Mendelian randomization (MR) is a human genetics method for inferring causal relationships between risk factors and diseases. A common focus of MR studies has been on the causal inference of a single risk factor on a single disease. This has led to the successful discovery of numerous causal risk factors for disease. However, it remains unclear how much each causal risk factor contributes to disease collectively. Here, we introduce the concept of “causality explained,” that provides an estimator of the causal variance explained by a phenome‐wide set of risk factors on complex diseases to assess how much causality can be potentially explained. The model is based on principal component regression which is a multivariate linear regression based on principal component analysis. In complement, we propose the “polyfactorial index” to assess the trajectory of causality explained as risk factors are sequentially added into the model, to characterize the causal architecture for a complex disease. We demonstrate that our model correctly assesses the causality explained and causal architecture in simulations across a wide range of parameters. To build our model, we used a phenome‐wide set of 222 traits from the UK Biobank compared to a set of 5 known risk factors for coronary artery disease. We observed that the phenome‐wide set explains more than 45% of causality compared to 28.76% for the set of known risk factors. In addition, we tested our approach on 13 complex diseases and showed that the phenome‐wide set can explain between 27% for anorexia to 80% for schizophrenia, with ever increasing trajectories of causality explained. We propose the “omnicausal model,” which posits that a large number of risk factors individually explains a small amount to disease but collectively explain most of the causal variance. We distinguished core and peripheral causal factors that explain respectively a larger and a smaller part of causal variance. This approach provides insights into the underlying causal architecture between risk factors and disease.
- 1 August 2026
- Published by Wiley in Genetic Epidemiology
- Vol. 50 (6) , e70052
Open AccessThe Omnicausal Model Reveals the Highly Polyfactorial Nature of Complex Diseases
Mendelian randomization (MR) is a human genetics method for inferring causal relationships between risk factors and diseases. A common focus of MR studies has been on the causal inference of a single risk factor on a single disease. This has led to the successful discovery of numerous causal risk factors for disease. However, it remains unclear how much each causal risk factor contributes to disease collectively. Here, we introduce the concept of “causality explained,” that provides an estimator of the causal variance explained by a phenome‐wide set of risk factors on complex diseases to assess how much causality can be potentially explained. The model is based on principal component regression which is a multivariate linear regression based on principal component analysis. In complement, we propose the “polyfactorial index” to assess the trajectory of causality explained as risk factors are sequentially added into the model, to characterize the causal architecture for a complex disease. We demonstrate that our model correctly assesses the causality explained and causal architecture in simulations across a wide range of parameters. To build our model, we used a phenome‐wide set of 222 traits from the UK Biobank compared to a set of 5 known risk factors for coronary artery disease. We observed that the phenome‐wide set explains more than 45% of causality compared to 28.76% for the set of known risk factors. In addition, we tested our approach on 13 complex diseases and showed that the phenome‐wide set can explain between 27% for anorexia to 80% for schizophrenia, with ever increasing trajectories of causality explained. We propose the “omnicausal model,” which posits that a large number of risk factors individually explains a small amount to disease but collectively explain most of the causal variance. We distinguished core and peripheral causal factors that explain respectively a larger and a smaller part of causal variance. This approach provides insights into the underlying causal architecture between risk factors and disease.
- Open Access
- 30 June 2026
- Published by Sungkyunkwan University School of Medicine in Precision and Future Medicine
- Vol. 10 (2) , 77-89
Micronutrients in psychiatric and neurodevelopmental disorders
Purpose: Micronutrients are essential for brain function, but whether their reported associations with psychiatric and neurodevelopmental disorders are causal remains unclear. We evaluated these associations systematically by integrating evidence from an umbrella review and Mendelian randomization (MR) analyses.Methods: Systematic searches of PubMed and Embase (PROSPERO CRD42023468700) identified 26 eligible meta-analyses of observational studies. MR analyses examined 14 micronutrients and 12 disorders using genome-wide association summary statistics from individuals of European ancestry, with sensitivity analyses including weighted median, MR-Egger, and MR-PRESSO.Results: Among 168 micronutrient–disorder associations, none reached statistical significance in both observational and MR analyses. Several associations showed directionally consistent patterns across independent observational studies or between observational and MR results, but only zinc–autism spectrum disorder (ASD) and vitamin D–major depressive disorder (MDD) were concordant across both evidence streams. Individuals with ASD had lower circulating zinc levels than controls (standardized mean difference, –0.36; 95% confidence interval [CI], –0.67 to –0.05), while genetically predicted higher zinc levels showed a suggestive association with lower ASD risk (odds ratio [OR], 0.91; 95% CI, 0.83 to 1.00; P= 0.055). For vitamin D–MDD, observational evidence indicated lower serum vitamin D levels in MDD (Hedges’ g, –0.35; 95% CI, –0.49 to –0.20), with a concordant but non-significant MR estimate (OR, 0.92; 95% CI, 0.83 to 1.01; P= 0.085).Conclusion: MR provided limited evidence for causality, suggesting that observed micronutrient differences may largely reflect the downstream effects of psychiatric illness. Zinc–ASD and vitamin D–MDD warrant further longitudinal and interventional investigation.
- 30 June 2026
- Published by Sungkyunkwan University School of Medicine in Precision and Future Medicine
- Vol. 10 (2) , 77-89
Open AccessMicronutrients in psychiatric and neurodevelopmental disorders
Purpose: Micronutrients are essential for brain function, but whether their reported associations with psychiatric and neurodevelopmental disorders are causal remains unclear. We evaluated these associations systematically by integrating evidence from an umbrella review and Mendelian randomization (MR) analyses.Methods: Systematic searches of PubMed and Embase (PROSPERO CRD42023468700) identified 26 eligible meta-analyses of observational studies. MR analyses examined 14 micronutrients and 12 disorders using genome-wide association summary statistics from individuals of European ancestry, with sensitivity analyses including weighted median, MR-Egger, and MR-PRESSO.Results: Among 168 micronutrient–disorder associations, none reached statistical significance in both observational and MR analyses. Several associations showed directionally consistent patterns across independent observational studies or between observational and MR results, but only zinc–autism spectrum disorder (ASD) and vitamin D–major depressive disorder (MDD) were concordant across both evidence streams. Individuals with ASD had lower circulating zinc levels than controls (standardized mean difference, –0.36; 95% confidence interval [CI], –0.67 to –0.05), while genetically predicted higher zinc levels showed a suggestive association with lower ASD risk (odds ratio [OR], 0.91; 95% CI, 0.83 to 1.00; P= 0.055). For vitamin D–MDD, observational evidence indicated lower serum vitamin D levels in MDD (Hedges’ g, –0.35; 95% CI, –0.49 to –0.20), with a concordant but non-significant MR estimate (OR, 0.92; 95% CI, 0.83 to 1.01; P= 0.085).Conclusion: MR provided limited evidence for causality, suggesting that observed micronutrient differences may largely reflect the downstream effects of psychiatric illness. Zinc–ASD and vitamin D–MDD warrant further longitudinal and interventional investigation.
- Open Access
- 11 June 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Genetically supported drug target prioritization for rare diseases
The online version contains supplementary material available at 10.1186/s13073-026-01671-5.
- 11 June 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Open AccessGenetically supported drug target prioritization for rare diseases
The online version contains supplementary material available at 10.1186/s13073-026-01671-5.
- Open Access
Resolving inflammatory bowel disease risk variants to genes and cell types
Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
Open AccessResolving inflammatory bowel disease risk variants to genes and cell types
Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
- Open Access
- 16 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD). Although Lp(a) is a genetically determined risk factor, the plasma proteomic features associated with Lp(a) and whether they provide information about ASCVD risk beyond Lp(a) concentration are not well characterized. OBJECTIVE: We sought to identify plasma proteomic features associated with Lp(a) concentration and to evaluate whether an Lp(a)-associated proteomic signature is associated with ASCVD phenotypes in young, healthy adults. METHODS: In the Coronary Artery Risk Development in Young Adults (CARDIA) study, we measured year 7 Lp(a) and 184 cardiovascular proteins using the Olink proximity extension assay in 3,920 participants without prior coronary heart disease. Lp(a)-associated proteomic signatures were derived using least absolute shrinkage and selection operator (LASSO) regression in a split-sample design and tested for association with coronary artery calcification (CAC), incident coronary heart disease (CHD), and high-sensitivity C-reactive protein (hs-CRP) over 27 years of follow-up. External replication was performed in the UK Biobank ( n = 37,996). RESULTS: Lp(a) was associated with CAC (OR 1.23 [1.13–1.34]; P < 0.0001) and incident CHD (HR 1.23 [1.07–1.41]; P = 0.004). Lp(a) was correlated with proteomic features reflecting immune activation, coagulation, and vascular dysfunction. A quantitative Lp(a)-associated proteomics score was independently associated with incident CAC (standardized β = 0.40, P < 0.0001) and hs-CRP (standardized β = 0.11, P = 0.00015) after adjustment for Lp(a) concentration. In the UK Biobank, a recalibrated Lp(a)-associated proteomics score was associated with CRP, incident CHD, and all-cause mortality. CONCLUSIONS: In young adults, Lp(a) was associated with distinct proteomic features that independently predicted ASCVD phenotypes beyond Lp(a) concentration, generating hypotheses regarding biological pathways linked to Lp(a)-related cardiovascular risk. FUNDING: VA MERIT grant (1I01CX002560); Taubman Medical Research Institute (Wolfe Scholarship); National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), NIH (U01DK123013-03); National Institute on Aging (NIA), NIH (R01AG059729); National Heart, Lung and Blood Institute (NHLBI), NIH (R01HL136685); American Heart Association Strategically Focused Research Network grant in Cardiometabolic Disease (funded proteomics in CARDIA); NIH (K23MD017253 and R01HL167733); Blue Cross Blue Shield of Michigan Foundation; A. Alfred Taubman Medical Research Institute; National Institute of Nursing Research (R01NR019628); National Institute of General Medical Sciences (NIGMS), NIH (R35-GM124836). The CARDIA study was conducted and supported by the NHLBI in collaboration with the University of Alabama at Birmingham (75N92023D00002 and 75N92023D00005), Northwestern University (75N92023D00004), University of Minnesota (75N92023D00006), and the Kaiser Foundation Research Institute (75N92023D00003). ROLE OF FUNDING SOURCE: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
- 16 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
Open AccessLipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD). Although Lp(a) is a genetically determined risk factor, the plasma proteomic features associated with Lp(a) and whether they provide information about ASCVD risk beyond Lp(a) concentration are not well characterized. OBJECTIVE: We sought to identify plasma proteomic features associated with Lp(a) concentration and to evaluate whether an Lp(a)-associated proteomic signature is associated with ASCVD phenotypes in young, healthy adults. METHODS: In the Coronary Artery Risk Development in Young Adults (CARDIA) study, we measured year 7 Lp(a) and 184 cardiovascular proteins using the Olink proximity extension assay in 3,920 participants without prior coronary heart disease. Lp(a)-associated proteomic signatures were derived using least absolute shrinkage and selection operator (LASSO) regression in a split-sample design and tested for association with coronary artery calcification (CAC), incident coronary heart disease (CHD), and high-sensitivity C-reactive protein (hs-CRP) over 27 years of follow-up. External replication was performed in the UK Biobank ( n = 37,996). RESULTS: Lp(a) was associated with CAC (OR 1.23 [1.13–1.34]; P < 0.0001) and incident CHD (HR 1.23 [1.07–1.41]; P = 0.004). Lp(a) was correlated with proteomic features reflecting immune activation, coagulation, and vascular dysfunction. A quantitative Lp(a)-associated proteomics score was independently associated with incident CAC (standardized β = 0.40, P < 0.0001) and hs-CRP (standardized β = 0.11, P = 0.00015) after adjustment for Lp(a) concentration. In the UK Biobank, a recalibrated Lp(a)-associated proteomics score was associated with CRP, incident CHD, and all-cause mortality. CONCLUSIONS: In young adults, Lp(a) was associated with distinct proteomic features that independently predicted ASCVD phenotypes beyond Lp(a) concentration, generating hypotheses regarding biological pathways linked to Lp(a)-related cardiovascular risk. FUNDING: VA MERIT grant (1I01CX002560); Taubman Medical Research Institute (Wolfe Scholarship); National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), NIH (U01DK123013-03); National Institute on Aging (NIA), NIH (R01AG059729); National Heart, Lung and Blood Institute (NHLBI), NIH (R01HL136685); American Heart Association Strategically Focused Research Network grant in Cardiometabolic Disease (funded proteomics in CARDIA); NIH (K23MD017253 and R01HL167733); Blue Cross Blue Shield of Michigan Foundation; A. Alfred Taubman Medical Research Institute; National Institute of Nursing Research (R01NR019628); National Institute of General Medical Sciences (NIGMS), NIH (R35-GM124836). The CARDIA study was conducted and supported by the NHLBI in collaboration with the University of Alabama at Birmingham (75N92023D00002 and 75N92023D00005), Northwestern University (75N92023D00004), University of Minnesota (75N92023D00006), and the Kaiser Foundation Research Institute (75N92023D00003). ROLE OF FUNDING SOURCE: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
- Open Access
Genetic Architecture and Myocardial Fibrotic Remodeling in Mitral Valve Prolapse
Mitral valve prolapse (MVP) is the most common cause of primary mitral regurgitation and is associated with the development of malignant arrhythmias, often in the context of myocardial fibrosis. The genetic architecture of MVP, and whether there are genetic factors explaining why only some individuals with MVP have adverse outcomes, remains poorly understood. We performed a meta-analysis of genome-wide association studies (GWAS) for MVP encompassing 21,517 cases among a total sample size of over 2.2 million individuals. We discovered 89 genomic risk loci for MVP, of which 72 were novel findings. Prioritization of causal genes and pathways using epigenetic and transcriptomic data from mitral valve and extra-valvular tissues replicated known gene associations to MVP including those involved in TGF-β signaling and extracellular matrix biology, but additionally emphasized a role in MVP for biological pathways relevant to cardiomyocyte biology. Accordingly, we identified several MVP risk loci with pleiotropy to cardiomyopathies, especially hypertrophic cardiomyopathy, and demonstrated a significant genetic correlation between MVP and hypertrophic cardiomyopathy. Finally, we interrogated snRNA-seq data in human papillary muscle tissue from two individuals with severe MVP, characterizing genes associated with both risk of papillary muscle fibrosis and MVP.
Open AccessGenetic Architecture and Myocardial Fibrotic Remodeling in Mitral Valve Prolapse
Mitral valve prolapse (MVP) is the most common cause of primary mitral regurgitation and is associated with the development of malignant arrhythmias, often in the context of myocardial fibrosis. The genetic architecture of MVP, and whether there are genetic factors explaining why only some individuals with MVP have adverse outcomes, remains poorly understood. We performed a meta-analysis of genome-wide association studies (GWAS) for MVP encompassing 21,517 cases among a total sample size of over 2.2 million individuals. We discovered 89 genomic risk loci for MVP, of which 72 were novel findings. Prioritization of causal genes and pathways using epigenetic and transcriptomic data from mitral valve and extra-valvular tissues replicated known gene associations to MVP including those involved in TGF-β signaling and extracellular matrix biology, but additionally emphasized a role in MVP for biological pathways relevant to cardiomyocyte biology. Accordingly, we identified several MVP risk loci with pleiotropy to cardiomyopathies, especially hypertrophic cardiomyopathy, and demonstrated a significant genetic correlation between MVP and hypertrophic cardiomyopathy. Finally, we interrogated snRNA-seq data in human papillary muscle tissue from two individuals with severe MVP, characterizing genes associated with both risk of papillary muscle fibrosis and MVP.
- Open Access
Whole-genome sequence genome-wide association study in All of Us identifies a novel glaucoma risk locus in African ancestry individuals
Objective: To assess how whole genome sequencing and varying phenotype definitions influence genetic discovery for primary open-angle glaucoma (POAG) in a diverse population. Design: Ancestry-stratified genome-wide association studies (GWASs) and cross-ancestry meta-analyses of POAG cases and controls using two phenotype definitions. Participants: Cases (age > 40) and controls (age > 65) were identified in the National Institutes of Health All of Us Research Program v8 data release and sub-divided into genetically inferred ancestral groups. Using the relaxed phenotype (ICD codes only), case/control counts were: European (1,846/84,654), African (1,042/15,966), and Latino/Admixed American (305/10,167). Using the stringent phenotype (ICD codes and evidence of glaucoma treatment in the electronic health record), case/control counts were: European (1,528/79,276), African (862/14,076), and Latino/Admixed American (250/9,668). Cross-ancestry meta-analyses included 3,193 cases/110,787 controls for the relaxed phenotype and 2,640 cases/103,020 controls for the stringent phenotype. Methods: GWASs were conducted within European, African, and Latino/Admixed American ancestry groups individually using firth logistic regression with age, sex, and the top 10 genotype principal components included as covariates. The ancestry-stratified GWASs were then meta-analyzed using a fixed-effects, inverse variance-weighted approach. Main Outcome Measures: Identification of genome-wide significant loci ( P < 5×10 -8 ) for POAG using different phenotype definitions and ancestry groups. Results: Known POAG risk loci (e.g., TMCO1 , CDKN2B-AS1 , and GMDS ) reached genome-wide significance in both the European GWASs and cross-ancestry meta-analyses (odds ratio (OR) range: 1.19–1.38). A novel risk locus near CYP2A7 (rs76935404[T], OR = 1.35) was identified in the African ancestry GWAS using the stringent phenotype definition. Effect sizes for known POAG risk loci from prior large-scale meta-analyses strongly correlated with effect sizes in this study (Pearson r = 0.75–0.84, P < 1 × 10⁻⁵ for all). The strength and consistency of these correlations support the robustness of the findings. Conclusions: This study demonstrates the value of whole genome sequencing, diverse ancestry inclusion, and phenotypic refinement in uncovering novel POAG genetic risk loci. The findings underscore the need to prioritize both genetic diversity and refined case/control definitions to advance understanding of this complex ocular disease. Précis: This study identifies a novel primary open-angle glaucoma risk locus in individuals of African ancestry using whole genome sequencing and varying phenotype definitions in the diverse All of Us Research Program dataset.
Open AccessWhole-genome sequence genome-wide association study in All of Us identifies a novel glaucoma risk locus in African ancestry individuals
Objective: To assess how whole genome sequencing and varying phenotype definitions influence genetic discovery for primary open-angle glaucoma (POAG) in a diverse population. Design: Ancestry-stratified genome-wide association studies (GWASs) and cross-ancestry meta-analyses of POAG cases and controls using two phenotype definitions. Participants: Cases (age > 40) and controls (age > 65) were identified in the National Institutes of Health All of Us Research Program v8 data release and sub-divided into genetically inferred ancestral groups. Using the relaxed phenotype (ICD codes only), case/control counts were: European (1,846/84,654), African (1,042/15,966), and Latino/Admixed American (305/10,167). Using the stringent phenotype (ICD codes and evidence of glaucoma treatment in the electronic health record), case/control counts were: European (1,528/79,276), African (862/14,076), and Latino/Admixed American (250/9,668). Cross-ancestry meta-analyses included 3,193 cases/110,787 controls for the relaxed phenotype and 2,640 cases/103,020 controls for the stringent phenotype. Methods: GWASs were conducted within European, African, and Latino/Admixed American ancestry groups individually using firth logistic regression with age, sex, and the top 10 genotype principal components included as covariates. The ancestry-stratified GWASs were then meta-analyzed using a fixed-effects, inverse variance-weighted approach. Main Outcome Measures: Identification of genome-wide significant loci ( P < 5×10 -8 ) for POAG using different phenotype definitions and ancestry groups. Results: Known POAG risk loci (e.g., TMCO1 , CDKN2B-AS1 , and GMDS ) reached genome-wide significance in both the European GWASs and cross-ancestry meta-analyses (odds ratio (OR) range: 1.19–1.38). A novel risk locus near CYP2A7 (rs76935404[T], OR = 1.35) was identified in the African ancestry GWAS using the stringent phenotype definition. Effect sizes for known POAG risk loci from prior large-scale meta-analyses strongly correlated with effect sizes in this study (Pearson r = 0.75–0.84, P < 1 × 10⁻⁵ for all). The strength and consistency of these correlations support the robustness of the findings. Conclusions: This study demonstrates the value of whole genome sequencing, diverse ancestry inclusion, and phenotypic refinement in uncovering novel POAG genetic risk loci. The findings underscore the need to prioritize both genetic diversity and refined case/control definitions to advance understanding of this complex ocular disease. Précis: This study identifies a novel primary open-angle glaucoma risk locus in individuals of African ancestry using whole genome sequencing and varying phenotype definitions in the diverse All of Us Research Program dataset.
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (3)
Three-year risk prediction of aortic stenosis using routine medical records: derivation and validation in 919 954 individuals from two cohorts
Aims: All-cause mortality ranges between 33% and 42% for individuals with untreated moderate to severe aortic stenosis (AS). Transcatheter aortic valve replacement makes this a treatable condition, if identified early. Machine learning-based tools show great promise to predict cardiovascular outcomes. Methods and results: We developed and validated a machine learning model for 3-year prediction of AS risk (ASrisk) using serum biomarkers and vital sign measurements. We then evaluated the tool’s capacity to identify diagnoses of AS sequelae, echocardiographic outcomes in individuals not diagnosed with AS, as well as enrichment and 3-year aortic valve area reduction in individuals with high ASrisk. Among 919 954 participants, 429 996 were from the Mount Sinai Data Warehouse (MSDW) [2179 (0.5%) AS cases] and 489 958 were from the UK Biobank [5066 (1%) AS cases]. Odds ratio (OR) of AS sequelae increased quantitatively with ascending deciles of ASrisk [OR 1.63 (95% CI 1.60–1.67) in MSDW]. Increasing ASrisk by 1 SD resulted in higher odds of echocardiographic findings in undiagnosed individuals [OR 1.88 (95% CI 1.71–2.06) for Doppler velocity index, OR 2.50 (95% CI 2.36–2.64) for aortic valve area, and OR 2.61 (95% CI 1.89–2.71) for mean gradient]. Three years after risk assessment, individuals with ASrisk > 0.95 show an 11-fold enrichment for AS diagnosis in both cohorts and an average reduction in aortic valve area of 0.42 cm2. Conclusion: ASrisk can predict risk of AS 3 years ahead of diagnosis in the general population.
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (3)
Open AccessThree-year risk prediction of aortic stenosis using routine medical records: derivation and validation in 919 954 individuals from two cohorts
Aims: All-cause mortality ranges between 33% and 42% for individuals with untreated moderate to severe aortic stenosis (AS). Transcatheter aortic valve replacement makes this a treatable condition, if identified early. Machine learning-based tools show great promise to predict cardiovascular outcomes. Methods and results: We developed and validated a machine learning model for 3-year prediction of AS risk (ASrisk) using serum biomarkers and vital sign measurements. We then evaluated the tool’s capacity to identify diagnoses of AS sequelae, echocardiographic outcomes in individuals not diagnosed with AS, as well as enrichment and 3-year aortic valve area reduction in individuals with high ASrisk. Among 919 954 participants, 429 996 were from the Mount Sinai Data Warehouse (MSDW) [2179 (0.5%) AS cases] and 489 958 were from the UK Biobank [5066 (1%) AS cases]. Odds ratio (OR) of AS sequelae increased quantitatively with ascending deciles of ASrisk [OR 1.63 (95% CI 1.60–1.67) in MSDW]. Increasing ASrisk by 1 SD resulted in higher odds of echocardiographic findings in undiagnosed individuals [OR 1.88 (95% CI 1.71–2.06) for Doppler velocity index, OR 2.50 (95% CI 2.36–2.64) for aortic valve area, and OR 2.61 (95% CI 1.89–2.71) for mean gradient]. Three years after risk assessment, individuals with ASrisk > 0.95 show an 11-fold enrichment for AS diagnosis in both cohorts and an average reduction in aortic valve area of 0.42 cm2. Conclusion: ASrisk can predict risk of AS 3 years ahead of diagnosis in the general population.
- Open Access
Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations
Background: Circulating lipoprotein(a) [Lp(a)] levels are highly heritable and linked to atherosclerotic cardiovascular disease, yet clinical measurement rates remain low (125 nmol/L) through positive predictive value (PPV) and number needed to test (NNT). Results: Among PMBB (n = 1856), MGBB (n = 1401), and BioMe (n = 1686) participants with available genotype and Lp(a) measurements, average age was 60 years, and 51% were female. Overall r2 of the haplotype model was 0.46 (95% Credible Interval [CrI] 0.32 to 0.6), with similar performance across genetically inferred ancestries and cohorts. For identifying elevated Lp(a) levels >125 nmol/L the overall PPV was 0.81 (95% CrI 0.6 to 0.89), corresponding to a NNT of 1.2 (95% CrI 1.1 to 1.7) individuals predicted to have elevated levels needing to undergo clinical testing to identify one true elevation. In the full PMBB cohort (n = 49310), the haplotype model identified elevated Lp(a) at a rate of 128 per 1000 (95% CrI 125 to 130), corresponding to an estimated 14.4-fold improvement (95% CrI 13.1 to 15.9; P(improvement) = 1) in identification rate compared with the existing rate of clinical assessment. Conclusions: A haplotype-based genetic model effectively identified individuals with elevated Lp(a) levels across diverse populations, with potential utility for opportunistic screening among cohorts where genotype data is available, but Lp(a) testing rates are low.
Open AccessGenetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations
Background: Circulating lipoprotein(a) [Lp(a)] levels are highly heritable and linked to atherosclerotic cardiovascular disease, yet clinical measurement rates remain low (125 nmol/L) through positive predictive value (PPV) and number needed to test (NNT). Results: Among PMBB (n = 1856), MGBB (n = 1401), and BioMe (n = 1686) participants with available genotype and Lp(a) measurements, average age was 60 years, and 51% were female. Overall r2 of the haplotype model was 0.46 (95% Credible Interval [CrI] 0.32 to 0.6), with similar performance across genetically inferred ancestries and cohorts. For identifying elevated Lp(a) levels >125 nmol/L the overall PPV was 0.81 (95% CrI 0.6 to 0.89), corresponding to a NNT of 1.2 (95% CrI 1.1 to 1.7) individuals predicted to have elevated levels needing to undergo clinical testing to identify one true elevation. In the full PMBB cohort (n = 49310), the haplotype model identified elevated Lp(a) at a rate of 128 per 1000 (95% CrI 125 to 130), corresponding to an estimated 14.4-fold improvement (95% CrI 13.1 to 15.9; P(improvement) = 1) in identification rate compared with the existing rate of clinical assessment. Conclusions: A haplotype-based genetic model effectively identified individuals with elevated Lp(a) levels across diverse populations, with potential utility for opportunistic screening among cohorts where genotype data is available, but Lp(a) testing rates are low.